Modern Pediatrics. Ukraine. (2026).1(153): 90-95. doi: 10.15574/SP.2026.1(153).9095
Hula Ya. T.¹, Dubei L. Ya.^2
1Lviv Regional Oncological Treatment and Diagnostic Center, Ukraine
²Danylo Halytsky Lviv National Medical University, Ukraine

For citation: Hula YaT, Dubei LYa. (2026). Clinical characteristics of antitumor therapy complications in adolescents and young adults with lymphomas. Modern Pediatrics. Ukraine. 1(153): 90-95. doi: 10.15574/SP.2026.1(153).9095.
Article received: Dec 01, 2025. Accepted for publication: Feb 08, 2026.

Analysis of the structure and incidence of complications depending on the lymphoma subtype is essential for optimizing supportive care and individualizing therapeutic approaches.
Aim – to analyze the incidence, structure, and characteristics of infectious and non-infectious (toxic) complications of antitumor therapy in patients with different types of lymphomas.
Materials and methods. The study included 120 patients aged 14-40 with various histological types of lymphoma who received polychemotherapy according to internationally accepted protocols. The cohort comprised patients with Hodgkin lymphoma (n=54), B-cell non-Hodgkin lymphomas (n=36), T/T-NK-cell non-Hodgkin lymphomas (n=18), and lymphoblastic lymphomas (n=12). Complications were assessed throughout the entire period of active treatment. Non-infectious toxic complications were evaluated based on grade III–IV hematologic toxicity, gastrointestinal disorders, cardiotoxicity, and neurotoxicity.
Results. Infectious complications were registered in 37.5% of patients, with febrile neutropenia being the most common (20.8%). Its incidence was significantly higher in patients with T/T-NK-cell NHL and lymphoblastic lymphomas (33.3%) compared to Hodgkin lymphoma (13.0%) (p=0.015). Septic conditions occurred in 4.2% of cases. Non-infectious toxic complications were more frequent and varied according to lymphoma type: grade III-IV hematologic toxicity was observed in 32.5% of patients (up to 66.7% in lymphoblastic lymphomas; p=0.001), gastrointestinal disorders in 17.5%, cardiotoxicity in 10.0%, and neurotoxicity in 10.0%. The lowest complication rates were observed in Hodgkin lymphoma, while the highest were found in aggressive forms of NHL.
Conclusions. The incidence and structure of complications of antitumor therapy in lymphomas significantly depend on the histological subtype and treatment intensity. Patients with aggressive forms of NHL have a substantially higher risk of infectious and severe toxic complications, requiring enhanced monitoring, active prevention of febrile neutropenia, and individualized supportive care strategies.
The study was conducted in accordance with the principles of the Declaration of Helsinki. Informed parental consent was obtained for participation in the study.
The authors declare no conflict of interest
Keywords: Hodgkin lymphoma, non-Hodgkin lymphoma, febrile neutropenia, hematologic toxicity, infectious complications, polychemotherapy.

REFERENCES:

1. Antherieu G, Thibaud V, Sesques P, Jacot W, Menia K et al. (2025). Neutropenic events associated with new anticancer drugs. Support Care Cancer. 33: 1161. https://doi.org/10.1007/s00520-025-10141-4; PMid:41331540 PMCid:PMC12672706

2. Asian Biomedicine. (2025, Sep 2). Prevention of febrile neutropenia in diffuse large B-cell lymphoma treated with R-CHOP. Asian Biomed (Res Rev News). 19(4): 164. https://doi.org/10.2478/abm-2025-0020; PMid:40904613 PMCid:PMC12404657

3. Choi YW, Jeong SH, Ahn MS, Lee HW, Kang SY, Choi JH et al. (2014). Patterns of neutropenia and risk factors for febrile neutropenia of DLBCL patients treated with R-CHOP. J Korean Med Sci. 29(11): 1493-1500. https://doi.org/10.3346/jkms.2014.29.11.1493; PMid:25408580 PMCid:PMC4234916

4. Kim DY, Nam J, Chung JS, Jeon BE, Lee JH, Jo JC et al. (2022). Predictive parameters of febrile neutropenia and clinical significance of G-CSF receptor signaling pathway. Cancer Res Treat. 54(4): 1256-1267. https://doi.org/10.4143/crt.2021.944; PMid:34990523 PMCid:PMC9582470

5. Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M et al. (2016). Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Annals of Oncology. 27: 111-118. https://doi.org/10.1093/annonc/mdw325; PMid:27664247

6. Morimoto M, Yokoya Y, Yoshida K, Kosako H, Hori Y, Mushino T et al. (2024). Predictive Model for Occurrence of Febrile Neutropenia after Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma: A Multicenter, Retrospective, Observational Study. Hematology Reports. 16(1): 76-88. https://doi.org/10.3390/hematolrep16010008; PMid:38390940 PMCid:PMC10885064

7. Penack O, Peczynski C, Boreland W, Wolff D, Moiseev I, Schoemans H et al. (2024). Management of complications of chimeric antigen receptor T-cell therapy: a report by the European Society of Blood and Marrow Transplantation. Haematologica. 109(11). https://doi.org/10.3324/haematol.2023.284810; PMid:38813730 PMCid:PMC11532686

8. Sandherr M, Stemler J, Schalk E, Hattenhauer T, Hentrich M, Hertenstein B et al. (2025). 2024 update of the AGIHO guideline on diagnosis and management of febrile neutropenia. Lancet Reg Health Eur. 51: 101214. https://doi.org/10.1016/j.lanepe.2025.101214; PMid:39973942 PMCid:PMC11836497

9. Stohs EJ, Abbas A, Freifeld A. (2024). Approach to febrile neutropenia in patients undergoing treatments for hematologic malignancies. Transpl Infect Dis. 6(2): e14236. https://doi.org/10.1111/tid.14236; PMid:38349035

10. Zheng W, Chen Z, Zhu S, Cheng L, Hu Y, Yang Y et al. (2023). Incidence and risk factors for febrile neutropenia in patients with diffuse large B-cell lymphoma receiving R-CHOP-21 in China. Support Care Cancer. 32(1): 43. https://doi.org/10.1007/s00520-023-08250-z; PMid:38200251 PMCid:PMC10781841